Harmony Biosciences
HRMY
326 hedge funds and large institutions have $1.97B invested in Harmony Biosciences in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 131 increasing their positions, 107 reducing their positions, and 33 closing their positions.
58% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 33
26% more capital invested
Capital invested by funds: $1.57B → $1.97B (+$402M)
22% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 107
5% more funds holding
Funds holding: 311 → 326 (+15)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less call options, than puts
Call options by funds: $7.83M | Put options by funds: $8M
3.22% less ownership
Funds ownership: 96.79% → 93.56% (-3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
Valor Management
Chicago,
Illinois
|
+$22.1M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$13.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.1M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$10M |
| 5 |
6CM
683 Capital Management
New York
|
+$9.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$35.8M |
| 2 |
Goldman Sachs
New York
|
-$26.4M |
| 3 |
Millennium Management
New York
|
-$20M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$13.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.4M |
HRMY Hedge Fund Activity: Q2 2026 in Review
326 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2026, worth a combined $1.97B — up 26% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new HRMY positions and 33 closed out — a net gain of 19 holders — while 131 added to existing stakes and 107 trimmed.
The largest buyer was Valor Management, adding an estimated $22.1M. The largest seller was SG Americas Securities, cutting an estimated $35.8M.
- 326 institutional investors held Harmony Biosciences (HRMY) as of Q2 2026, up from 311 in Q1 2026.
- Funds reported $1.97B of Harmony Biosciences stock for Q2 2026, up 26% quarter-over-quarter.
- 52 funds opened new Harmony Biosciences positions in Q2 2026 and 33 closed out, a net change of +19 holders.
- The largest Harmony Biosciences buyer in Q2 2026 was Valor Management, an estimated $22.1M added.
- The largest Harmony Biosciences seller in Q2 2026 was SG Americas Securities, an estimated $35.8M sold.
Based on aggregated 13F filings for Q2 2026.